Particularly interesting in this post is the comment from MJF about the need to be able to recognise and measure the disease through what’s described as markers.
We’re working on a different approach with some relationship to behavioural assessments and looking to kick off numerous research projects to extend the science.
Donor of the Day: Lily Safra – WSJ.com
Lily Safra wants to chart the course of Parkinson’s disease in order to stop it.
The widow of the banker Edmond J. Safra is giving $2.5 million to the New York-based Michael J. Fox Foundation to help fund a clinical study to help track the progression of Parkinson’s disease.
Bringing together pharmaceutical companies, nonprofits, scientists and private funders, Ms. Safra’s lead gift will help form a public-private partnership to fund the five-year $40 million Parkinson’s Progression Markers Initiative, which will use neuro-imaging, testing of biologic samples and behavioral assessments of 600 participants to identify so-called biomarkers of Parkinson’s disease.
Ms. Hood says most researchers are currently creating therapies that treat only the symptoms of the disease, such as tremors or ease of motion, rather than attacking the underling course of the disease.
“If the industry came up with a treatment for this chronic neurodegenerative disease, it would be a massive blockbuster but no one wants to do it alone,” she says. “Our board came to the discussion that if we want to find a cure for Parkinson’s one day, we have no choice but to pursue this major roadblock.”